会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 40. 发明申请
    • Compositions and methods for preventing erythropoietin-associated hypertension
    • 用于预防红细胞生成素相关性高血压的组合物和方法
    • US20050255112A1
    • 2005-11-17
    • US10848689
    • 2004-05-17
    • Jong LeeMary LeeJohn Lee
    • Jong LeeMary LeeJohn Lee
    • A61K38/18A61K39/395C07K16/28
    • A61K39/39533A61K38/179A61K38/1816A61K39/3955A61K2039/505A61K2121/00A61K2300/00C07K16/2863C07K2317/55
    • The inventors have discovered that both soluble erythropoietin-binding protein and antibodies against the erythropoietin-binding protein, when they are administered to a mammal along with erythropoietin (Epo), prevent or reduce the blood pressure increase normally caused by erythropoietin, while not affecting the hematocrit increase that is the purpose of Epo treatment. The invention provides a method of treating anemia in a mammal involving: administering erythropoietin (Epo) to the mammal; and administering to the mammal an agent selected from a soluble Epo-binding protein (Epo-bp), a recognition protein that binds Epo receptor on an extracellular soluble portion of the Epo receptor, and a combination thereof. The invention also provides a method of reducing hypertension in a mammal receiving Epo, and pharmaceutical compositions containing a soluble Epo-bp and/or a recognition protein that binds Epo receptor on an extracellular soluble portion of the Epo receptor
    • 本发明人已经发现,当将可溶性促红细胞生成素结合蛋白和抗红细胞生成素结合蛋白的抗体与促红细胞生成素(Epo)一起施用于哺乳动物时,可预防或降低通常由促红细胞生成素引起的血压升高,同时不影响促红细胞生成素结合蛋白 血细胞比容增加是Epo治疗的目的。 本发明提供一种治疗哺乳动物的贫血的方法,涉及:向哺乳动物施用促红细胞生成素(Epo); 以及向哺乳动物施用选自可溶性Epo结合蛋白(Epo-bp),结合Epo受体的细胞外可溶部分上的Epo受体的识别蛋白及其组合的药剂。 本发明还提供一种降低接受Epo的哺乳动物高血压的方法,以及含有可溶于Epo-bp和/或识别蛋白的药物组合物,该可溶性Epo-bp和/或识别蛋白结合Epo受体在Epo受体的细胞外可溶部分上